Precigen Inc (OQ:PGEN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Tel: N/A
IR: See website
Key People
Randal Joe Kirk
Executive Chairman of the Board
Helen Sabzevari
President, Chief Executive Officer, President - Precigen, Inc.
Rick L. Sterling
Chief Financial Officer
Jeffrey T. Perez
Senior Vice President - Intellectual Property Affairs
Donald P. Lehr
Chief Legal Officer
Business Overview
Precigen, Inc., formerly Intrexon Corporation, forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.
Financial Overview
For the nine months ended 30 September 2020,Precigen Inc revenues increased 14% to $83.8M. Net lossbefore extraordinary items decreased 23% to $102.8M.Revenues reflect an increase in demand for the Company'sproducts and services due to favorable market conditions.Lower net loss reflects Research and development -Balancing val decrease of 43% to $43.9M (expense).
Employees: 770 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $1,789M as of Sep 30, 2020
Annual revenue (TTM): $92.20M as of Sep 30, 2020
EBITDA (TTM): -$81.13M as of Sep 30, 2020
Net annual income (TTM): -$155.86M as of Sep 30, 2020
Free cash flow (TTM): -$103.44M as of Sep 30, 2020
Net Debt Last Fiscal Year: $81.12M as of Sep 30, 2020
Shares outstanding: 185,462,551 as of Oct 31, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.